Diana R. Tomchick

Mar 10, 2024 | nature.com | Mahmoud Ahmed |Nicholas T. Lam |Ivan Menendez-Montes |Ilaria Secco |Mateusz D. Tomczyk |Diana R. Tomchick | +4 more

AbstractTargeting Meis1 and Hoxb13 transcriptional activity could be a viable therapeutic strategy for heart regeneration. In this study, we performd an in silico screening to identify FDA-approved drugs that can inhibit Meis1 and Hoxb13 transcriptional activity based on the resolved crystal structure of Meis1 and Hoxb13 bound to DNA.

Oct 24, 2023 | nature.com | Diana R. Tomchick

AbstractStimulation of autophagy could provide powerful therapies for multiple diseases, including cancer and neurodegeneration. An attractive drug target for this purpose is Bcl-2, which inhibits autophagy by binding to the Beclin 1 BH3-domain. However, compounds that preclude Beclin 1/Bcl-2 binding might also induce apoptosis, which is inhibited by binding of Bcl-2 to BH3-domains of pro-apoptosis factors such as Bax.